NCT00324077

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.

Conditions

• Myeloid Leukemia, Chronic, Chronic-Phase

Interventions

Type	Name	Description
DRUG	Dasatinib in combination with imatinib

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-02-01
• First posted: 2006-05-10
• Last updated: 2016-02-17

Locations

3 sites across 1 country: United States